2001
ZD1839 (Iressa™) In Non–Small-Cell Lung Cancer
Herbst R, Khuri F, Fossella F, Glisson B, Kies M, Pisters K, Riddle J, Terry K, Lee J. ZD1839 (Iressa™) In Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2001, 3: 27-32. PMID: 14656386, DOI: 10.3816/clc.2001.n.014.Peer-Reviewed Original ResearchEpidermal growth factor receptorCell lung cancerAdvanced diseaseLung cancerPhase III clinical developmentEGFR tyrosine kinase inhibitorsAcceptable tolerability profileSelective EGFR tyrosine kinase inhibitorNSCLC cell linesTumor cell growthGrowth factor receptorAdvanced NSCLCTolerability profileNSCLC patientsPoor prognosisClinical activityMetastatic spreadInhibition of apoptosisPreclinical studiesHuman xenograftsClinical developmentTumor typesGrowth delayTumor progressionZD1839
1999
The proteasome inhibitor PS-341 in cancer therapy.
Teicher B, Ara G, Herbst R, Palombella V, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clinical Cancer Research 1999, 5: 2638-45. PMID: 10499643.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBoronic AcidsBortezomibBreast NeoplasmsCisplatinCyclophosphamideDipeptidesDrug SynergismHumansMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CProtease InhibitorsPyrazinesRadiation-Sensitizing AgentsTumor Cells, CulturedUbiquitinsConceptsProteasome inhibitor PS-341PS-341EMT-6/CDDP tumorAdditive tumor growth delayCancer therapyEMT-6/CTXTumor cell survival assayTumor growth delay assayLewis lung carcinomaColony-forming unit-granulocyte macrophageTumor growth delayGrowth delay assayHuman breast carcinoma cellsMCF-7 human breast carcinoma cellsUnit-granulocyte macrophageTumor cell killingCell survival assayBreast carcinoma cellsMetastatic diseaseInteresting new targetLung carcinomaRadiation therapyVivo resistanceGrowth delayParent tumor
1998
Acute in vivo resistance in high-dose therapy.
Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E. Acute in vivo resistance in high-dose therapy. Clinical Cancer Research 1998, 4: 483-91. PMID: 9516940.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCyclophosphamideDisease Models, AnimalDose-Response Relationship, DrugDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleMammary Neoplasms, ExperimentalMelphalanMiceMice, Inbred BALB CNeoplasm TransplantationPaclitaxelThiotepaConceptsTumor growth delayAdditive tumor growth delayHigh-dose cyclophosphamideHigh-dose melphalanGrowth delaySecond highest doseHigh doseSequential high-dose chemotherapyTumor cell survival assayEMT-6 mammary carcinomaTumor growth delay studiesBone marrow colony-forming unitsHigh-dose therapyMarrow colony-forming unitsHigh-dose chemotherapyBone marrow CFU-GMHigh-dose treatmentGrowth delay studiesTumor-bearing miceMarrow CFU-GMSolid tumor modelsCell survival assayCombination regimensMammary carcinomaCyclophosphamidePotential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Research 1998, 18: 2567-73. PMID: 9703911.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneAnimalsAnticarcinogenic AgentsAntineoplastic AgentsCarcinoma, Lewis LungCell DivisionCholestanolsCisplatinCombined Modality TherapyCyclophosphamideDoxorubicinDrug Therapy, CombinationFemaleFluorouracilMammary Neoplasms, ExperimentalMiceOxygenOxygen ConsumptionPaclitaxelPartial PressureRatsRats, Inbred F344ConceptsLewis lung carcinomaTumor growth delayPost-tumor implantationLung carcinomaGrowth delayLung metastasesTumor implantationMammary carcinomaTumor oxygenationDay 4Chemotherapeutic agentsPrimary Lewis lung tumorMurine Lewis lung carcinomaDaily subcutaneous injectionsLewis lung tumorTumor-bearing animalsModest effectCombination therapyContinuous infusionCytotoxic therapySystemic diseaseSubcutaneous injectionLung tumorsAntiangiogenic agentsHypoxic fraction
1997
PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher B, Ara G, Herbst R, Takeuchi H, Keyes S, Northey D. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo 1997, 11: 301-11. PMID: 9292296.Peer-Reviewed Original ResearchConceptsPEG-hemoglobinTumor growth delayMammary carcinomaTumor cell killingSolid tumorsTumor oxygenationGrowth delayDose of chemotherapyEMT-6 murine mammary carcinomaBone marrow CFU-GMEfficacy of chemotherapyEMT-6 tumorsMurine mammary carcinomaTumor-bearing miceCFU-GM survivalMarrow CFU-GMCell killingOxygen delivery agentEMT-6 tumor-bearing miceChemotherapy administrationLung metastasesMultiple dosesSingle dosesChemotherapyCFU-GM